

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/602,691
<b>Filing Date</b>	June 20, 2003
<b>First Named Inventor</b>	Sommadossi et al.
<b>Art Unit</b>	1623
<b>Examiner Name</b>	T.McIntosh III
<b>Attorney Docket No.</b>	11874-043-999

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	3,074,929	01/22/63	Hitchings, et al.	
	A02	4,022,889	05/01/77	Bannister et al.	
	A03	4,058,602	11/01/77	Beisler et al.	
	A04	4,239,753	12/01/80	Skulnick et al.	
	A05	5,246,924	09/01/93	Fox, et al.	
	A06	5,256,797	10/26/93	Chou, et al.	
	A07	5,539,116	07/23/96	Liotta, et al.	
	A08	5,565,438	10/15/96	Chu, et al.	
	A09	5,567,688	10/22/96	Chu, et al.	
	A10	5,587,362	12/24/96	Chu, et al.	
	A11	6,458,772	10/01/02	Zhou, et al.	
	A12	6,458,773	10/01/02	Gosselin, et al.	
	A13	6,596,700	07/22/03	Sommadossi, et al.	
	A14	6,642,206	11/01/03	Ramasamy et al.	
	A15	6,833,361	12/21/04	Hong, et al.	
	A16	6,946,115	09/20/05	Erion, et al.	
	A17	6,949,522	09/27/05	Otto, et al.	
	A18	6,965,066	11/15/05	Jiang, et al.	
	A19	7,144,868	12/05/06	Roberts, et al.	
	A20	7,151,089	12/19/06	Roberts, et al.	
	A21	7,157,434	01/02/07	Keicher, et al.	
	A22	11/644304	12/22/06	Mayes, et al.	
	A23	2002/0156030	10/24/02	Ramasamy et al.	
	A24	2003/0220290	11/27/03	Gosselin, et al.	
	A25	2004/0006002	01/08/04	Sommadossi, et al.	
	A26	2005/0137161	06/23/05	Sommadossi, et al.	
	A27	2006/0166865	07/27/06	Sommadossi, et al.	

LAI-3012156v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/602,691
	<b>Filing Date</b>	June 20, 2003
	<b>First Named Inventor</b>	Sommadossi et al.
	<b>Art Unit</b>	1623
	<b>Examiner Name</b>	T.McIntosh III
	<b>Attorney Docket No.</b>	11874-043-999

U.S. PATENT DOCUMENTS					
*Examiner Initials	Cite No.	Document Number – Kind Code	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28	2006/0199783	09/01/06	Wang, et al.	
	A29	2007/0060503	03/15/07	Gosselin, et al.	
	A30	2007/0060504	03/15/07	Gosselin, et al.	

FOREIGN PATENT DOCUMENTS						
*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	DE 1919307	01/14/71	Niedballa, et al.		
	B02	DE 2122991	11/16/72	Vorbruggen, et al.		
	B03	DE 2508312	09/02/76	Vorbruggen, et al.		
	B04	EP 0288847	04/16/88	Dobler, et al.		
	B05	EP 0494119	01/03/92	Belleau, et al.		
	B06	FR 1521076	04/12/68	Walton		
	B07	FR 1581628	09/19/69	Merck & Co. Inc.		
	B08	FR 2662165	11/22/91	Univ. Pier et Curie		
	B09	GB 1163102	09/04/69	Merck & Co. Inc.		
	B10	GB 924246	04/24/63	Wellcome Foundation, Ltd.		
	B11	GB 984877	03/03/65	Zellstofffabrik Waldhof		
	B12	JP 06228186	08/16/94	Yamasa Shoyu Co., Ltd.		
	B13	JP 48048495	09/21/71	Kojin Co. Ltd.		
	B14	JP 61263996	11/21/86	Boryung Pharmaceutical Co. Ltd.		
	B15	JP 63215694	09/08/88	Yamasa Shoyu Co. Ltd.		
	B16	JP 71021872	03/30/68	Sankyo Co., Ltd.		
	B17	WO 92/015308	09/17/92	Wellcome Foundation, Ltd.		
	B18	WO 92/018517	10/29/92	Cheng, et al.		
	B19	WO 01/032153	10/05/08	Biochem Pharma		

LAI-3012156v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

<b>Application Number</b>	10/602,691
<b>Filing Date</b>	June 20, 2003
<b>First Named Inventor</b>	Sommadossi et al.
<b>Art Unit</b>	1623
<b>Examiner Name</b>	T.McIntosh III
<b>Attorney Docket No.</b>	11874-043-999

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B20	WO 03/081899	06/26/03	Ribapharm Inc.		
	B21	WO 03/106577	12/24/03	Weikard, et al.		
	B22	WO 04/023921	03/25/04	Kim		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	AFDHAL, et al., Enhanced antiviral efficacy for valopicitabine plus PEG-interferon in hepatitis C patients with HCV genotype-1 infection. <i>Journal of Hepatology</i> 2005, Vol. 42, Supplement 2, p. 39-40.	
	C02	ALTMANN, et al., The Effects of 2'- and 3'-Alkyl Substituents on Oligonucleotide Hybridization and Stability, <i>Biorganic &amp; Medicinal Chemistry Letter</i> . 1994, 4, No. 16, 1969-74.	
	C03	BEIGELMAN <i>et al.</i> , "New synthesis of 2'-C-methylnucleosides starting from D-glucose and D-ribose" <i>Carbohydrate Res.</i> , 1987, 166, 219-232	
	C04	CAVELIER, F., et al., "Studies of Selective Boc Removal in the Presence of Silyl Ethers," <i>Tetrahedron Letters</i> , 37: 5131-5134 (1996).	
	C05	CHEN <i>et al.</i> , <i>Heterocycles</i> , vol. 28, no. 2, 1989, pp.593-601	
	C06	CLARK, et al., Synthesis and antiviral activity...", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 16, 2006, 1712-1715.	
	C07	DANIELS et al., "Tautomerism of Uracil and Thymine in Aqueous Solution: Spectroscopic Evidence", <i>Proc. Nat. Acad. Sci. USA</i> , Vol. 69, no. 9, pp. 2488-2491, 1972.	
	C08	FARQUHAR <i>et al.</i> , "Biologically reversible phosphate-protective groups," <i>J. Pharm. Sci.</i> , 1983, 72(3): 324	
	C09	FRANCESCO, et al. <i>Antiviral Research</i> 58 (2003) 1-16	
	C10	GEROTTO, et al., Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. <i>Journal of Virology</i> , September 1999, Vol. 73, No. 9, p. 7241-7247.	
	C11	GRUNNAGEL, et al., "Preparation of D-Tagatose." <i>Justus Liebigs Annalen der Chemie</i> (1969), 721: 234-5.	
	C12	HATTORI, H. <i>et al.</i> , "Nucleosides and Nucleotides 158" <i>Journal of Medicinal Chemistry, American Chemical Society</i> , Vol. 39, 1996, pp. 5005-5001	
	C13	HODGE, et al., "Amadori Rearrangement Products." <i>Methods in Carbohydrate Chemistry</i> (1963), 2: 99-107.	
	C14	HU, et al., Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2001, Vol. 8, p. 1-18.	
	C15	KERR, S.G., et al., "N-(Dialkylamino)Methylene Derivatives of 2'-Deoxycytidine and Arabinocytidine: Physicochemical Studies for Potential Prodrug Applications," <i>J. Pharm. Sci.</i> , 83(4): 582-586 (April 1994).	
	C16	KOHN, <i>et al.</i> , "A new method for the synthesis of furanose derivatives of aldohexoses." <i>J. Am. Chem. Soc.</i> , 1965, 87(23): 5475-80	

LAI-3012156v1

**EXAMINER  
SIGNATURE****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/602,691
	<b>Filing Date</b>	June 20, 2003
	<b>First Named Inventor</b>	Sommadossi et al.
	<b>Art Unit</b>	1623
	<b>Examiner Name</b>	T.McIntosh III
	<b>Attorney Docket No.</b>	11874-043-999

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C17	McFARLIN, et al., J. Am. Chem. Soc. 1958, 80, 5372-76.	
	C18	SCHEIBLER, C., "Ueber das Saccharin und die Saccharinsäure," Chemische Berichte, 13:2212-2217 (1880). In German.	
	C19	SHALABY, et al., "Conformations and Structure Studies of Sugar Lactones in the Solid State. Part 11. The Molecular Structure of a-D-Glucosaccharino-Y-Lactone: 2-C-Mehtyl-D-Ribo-Pentono-1,4-lactone." Carbohydrate Research (1994), 264(2), 191-8.	
	C20	SHI, et al., Synthesis and in vitro Anti-HCV Activity of β-d- and 1-2'-Deoxy-2'-Fluororibonucleosides, Nucleosides, Nucleotides & Nucleic Acids 2005, Volume 23, Numbers 5-7, pp. 875-879.	
	C21	SINKO, et al., Carrier-Mediated Intestinal Absorption of Valacyclovir, the L-Valyl Ester Prodrug of Acyclovir. BIOPHARMACEUTICS & DRUG DISPOSITION 1998, Vol. 19, pp. 209-217.	
	C22	SINKULA <i>et al.</i> , "Rationale for design of biologically reversible drug derivatives: prodrugs," <i>J. Pharm. Sci.</i> , 1975,64: 181-210	
	C23	SUNDBERG, et al., Advanced Organic Chemistry, Part b, 1990, pages 232 and 236.	
	C24	WALTON <i>et al.</i> , "Branched-chain sugar nucleosides. A new type of biologically active nucleoside," <i>J. Am. Chem. Soc.</i> , 88(19): 4524-25 (1966)	
	C25	WU, et al., Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Current Drug Targets - Infectious Disorders 2003, Vol. 3, p. 207-219.	
	C26	ZEDECK <i>et al.</i> , "Inhibition of the steroid induced synthesis of Δ5-3-ketosteroid isomerase in Pseudomonas testosteroni by a new purine deoxyribonucleoside analog: 6-chloro-8aza-9-cyclopentylpurine," <i>Mol. Phys.</i> , 3(4):386-95 (1967)	
	C27	ZHOU, et al., Pharmacokinetics and pharmacodynamics of valpicitabine. Journal of Hepatology 2005, Vol. 42 (Suppl. 2), p. 229.	
	C28	ZINCHENKO, et al., "2', 3' & .5' - uridine methyl derivatives in microbiological transelicozilation." Doklady Akad Nauk v.297(3), pp. 731-734 (1987).	
	C29	Office Action dated October 1, 2003 from application number 09/863,816.	
	C30	Notice of Allowance dated June 23, 2004 from application number 09/863,816.	
	C31	Office Action dated August 27, 2003 from application number 09/864,078.	
	C32	Notice of Allowance dated February 19, 2004 from application number 09/864,078.	
	C33	Notice of Allowance dated May 17, 2005 from application number 10/602,135.	
	C34	Office Action dated April 5, 2005 from application number 10/602,135.	
	C35	Notice of Allowance dated March 9, 2006 from application number 10/602,136.	
	C36	Office Action dated July 28, 2006 from application number 10/602,142.	
	C37	Office Action dated September 20, 2007 from application number 10/602,142.	
	C38	Office Action dated December 10, 2008 from application number 10/602,142.	
	C39	Office Action dated November 15, 2005 from application number 10/602,142.	

LAI-3012156v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>Application Number</b>	10/602,691
	<b>Filing Date</b>	June 20, 2003
	<b>First Named Inventor</b>	Sommadossi et al.
	<b>Art Unit</b>	1623
	<b>Examiner Name</b>	T.McIntosh III
	<b>Attorney Docket No.</b>	11874-043-999

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C40	Office Action dated March 29, 2007 from application number 10/602,142.	
	C41	Office Action dated February 26, 2008 from application number 10/602,142.	
	C42	Notice of Allowance dated December 28, 2005 from application number 10/602,692.	
	C43	Office Action dated April 5, 2005 from application number 10/602,692.	
	C44	Notice of Allowance dated December 27, 2005 from application number 10/602,693.	
	C45	Office Action dated April 6, 2005 from application number 10/602,693.	
	C46	Notice of Allowance dated December 27, 2005 from application number 10/602,694.	
	C47	Office Action dated April 6, 2005 from application number 10/602,694.	
	C48	Office Action dated September 10, 2004 from application number 10/602,976.	
	C49	Office Action dated May 19, 2005 from application number 10/602,976.	
	C50	Notice of Allowance dated October 13, 2005 from application number 10/602,976.	
	C51	Office Action dated 8/15/2006 from application number 10/608,907.	
	C52	Office Action dated 5/31/2007 from application number 10/608,907.	
	C53	Office Action dated 1/28/2008 from application number 10/608,907.	
	C54	Office Action dated November 26, 2008 from application number 10/608,907.	
	C55	Office Action dated August 2, 2006 from application number 10/609,298.	
	C56	Office Action dated July 10, 2008 from application number 10/609,298.	
	C57	Office Action dated October 5, 2005 from application number 11/005,440.	
	C58	Office Action dated December 5, 2006 from application number 11/005,440.	
	C59	Office Action dated June 13, 2007 from application number 11/005,440.	
	C60	Office Action dated October 16, 2007 from application number 11/005,440.	
	C61	Office Action dated August 21, 2006 from application number 11/005,441.	
	C62	Notice of Allowance dated June 22, 2007 from application number 11/005,441.	
	C63	Notice of Allowance dated January 8, 2008 from application number 11/005,441.	
	C64	Office Action dated August 7, 2006 from application number 11/005,442.	
	C65	Office Action dated May 16, 2007 from application number 11/005,442.	
	C66	Office Action dated November 28, 2007 from application number 11/005,442.	

LAI-3012156v1

<b>EXAMINER SIGNATURE</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	